Clinical Updatescolon cancerlean body mass
Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial
By MedXY|Oct 1, 2025
LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.